595 related articles for article (PubMed ID: 15939670)
1. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy.
Forman D; Tian C; Iacomini J
Mol Ther; 2005 Aug; 12(2):353-9. PubMed ID: 15939670
[TBL] [Abstract][Full Text] [Related]
2. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
3. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
6. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
Lee EN; Lee J; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Kwon CH; Joh JW; Kim SJ
J Surg Res; 2006 Jan; 130(1):102-9. PubMed ID: 16183077
[TBL] [Abstract][Full Text] [Related]
7. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
8. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
[TBL] [Abstract][Full Text] [Related]
9. Anti-mouse CD154 antibody treatment facilitates generation of mixed xenogeneic rat hematopoietic chimerism, prevents wasting disease and prolongs xenograft survival in mice.
Masaki H; Appel MC; Leahy L; Leif J; Paquin L; Shultz LD; Mordes JP; Greiner DL; Rossini AA
Xenotransplantation; 2006 May; 13(3):224-32. PubMed ID: 16756565
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
Zhu ZX; Fan LY; Wang Q
Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation for the induction of allo- and xenotolerance.
Sykes M
Clin Transplant; 1996 Aug; 10(4):357-63. PubMed ID: 8884109
[TBL] [Abstract][Full Text] [Related]
12. Alloresistance to K locus class I-mismatched bone marrow engraftment is mediated entirely by CD4+ and CD8+ T cells.
Hayashi H; LeGuern C; Sachs DH; Sykes M
Bone Marrow Transplant; 1996 Aug; 18(2):285-92. PubMed ID: 8864436
[TBL] [Abstract][Full Text] [Related]
13. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2003 Jul; 32(1):15-22. PubMed ID: 12815473
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
Taniguchi H; Abe M; Shirai T; Fukao K; Nakauchi H
J Immunol; 1995 Dec; 155(12):5631-6. PubMed ID: 7499847
[TBL] [Abstract][Full Text] [Related]
15. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
[TBL] [Abstract][Full Text] [Related]
16. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
[TBL] [Abstract][Full Text] [Related]
17. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-alpha beta monoclonal antibody, low dose irradiation, and donor bone marrow transfusion.
Nomoto K; Yung-Yun K; Omoto K; Umesue M; Murakami Y; Matsuzaki G; Nomoto K
Transplantation; 1995 Feb; 59(3):395-401. PubMed ID: 7871570
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD40L monoclonal antibodies can replace anti-CD4 monoclonal antibodies for the nonmyeloablative induction of mixed xenogeneic chimerism.
Ito H; Takeuchi Y; Shaffer J; Sykes M
Transplantation; 2006 Jul; 82(2):251-7. PubMed ID: 16858289
[TBL] [Abstract][Full Text] [Related]
19. Induction of tolerance by mixed chimerism with nonmyeloblative host conditioning: the importance of overcoming intrathymic alloresistance.
Nikolic B; Khan A; Sykes M
Biol Blood Marrow Transplant; 2001; 7(3):144-53. PubMed ID: 11302548
[TBL] [Abstract][Full Text] [Related]
20. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance.
Iwai T; Tomita Y; Zhang QW; Shimizu I; Nomoto K; Yasui H
Transpl Int; 2005 May; 17(12):795-803. PubMed ID: 15856178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]